Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer

International Journal of Molecular Medicine

Volumn 26, Issue 1, 2010, Pages 67-75

  Schott, Anne K ^a   Pries, Ralph ^a   Wollenberg, Barbara ^a  

^a Holstein Campus Lübeck   (Germany)

Author keywords

Head and neck cancer; Immuno modulation; T lymphocyte cells

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 7 RECEPTOR; MACROPHAGE DERIVED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UPREGULATION;

EID: 77954728157     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000436     Document Type: Article

References (64)

1. Luce D, Guenel P, Leclerc A, Brugere J, Point D and Rodriguez J: Alcohol and tobacco consumption in cancer of the mouth, pharynx, and larynx: a study of 316 female patients. Laryngoscope 98: 313-316, 1988. (Pubitemid 18092927)
2. Snow GB: Follow-up in patients treated for head and neck cancer: how frequent, how thorough and for how long? Eur J Cancer 28: 315-316, 1992.
3. Berrino F, Esteve J and Coleman MP: Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ, pp1-14, 1995.
4. St John MA, Abemayor E and Wong DT: Recent new approaches to the treatment of head and neck cancer. Anticancer Drugs 17: 365-375, 2006.
5. Kraunz KS, McClean MD, Nelson HH, Peters E, Calderon H and Kelsey KT: Duration but not intensity of alcohol and tobacco exposure predicts p16INK4A homozygous deletion in head and neck squamous cell carcinoma. Cancer Res 66: 4512-4515, 2006.
6. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG and Coman WB: Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 6: 1111-1118, 2006. (Pubitemid 44203388)
7. Bauernhofer T, Kuss I, Henderson B, Baum AS and Whiteside TL: Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33: 119-124, 2003.
8. Kross KW, Heimdal JH, Olsnes C, Olofsson J and Aarstad HJ: Head and neck squamous cell carcinoma spheroid- and monocyte spheroid-stimulated IL-6 and monocyte chemotactic protein-1 secretion are related to TNM stage, inflammatory state and tumor macrophage density. Acta Otolaryngol 125: 1097-1104, 2005.
9. Kuss I, Hathaway B, Ferris RL, Gooding W and Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755-3762, 2004.
10. Whiteside TL: Immunobiology of head and neck cancer. Cancer Metastasis Rev 24: 95-105, 2005.
11. McHugh RS and Shevach EM: The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 110: 693-702, 2002.
12. Miyara M and Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13: 108-116, 2007.
13. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
14. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL and Boyiadzis M: Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 15: 3325-3332, 2009.
15. + T cells secreting interleukin-10 and transforming growth factorbeta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354, 2007.
16. Whiteside TL: Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 3: 46-55, 2001.
17. Whiteside TL: 22. Immune responses to malignancies. J Allergy Clin Immunol 111: S677-S686, 2003.
18. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15, 2006.
19. Ferrone S and Whiteside TL: Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16: 755-774, viii, 2007.
20. + immunoregulatory T cells. Immunol Cell Biol 84: 487-501, 2006.
21. + regulatory T cells in cancer and autoimmunity. Curr Med Chem 14: 649-666, 2007.
22. Wang HY and Wang RF: Regulatory T cells and cancer. Curr Opin Immunol 19: 217-223, 2007.
23. Von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol 6: 338-344, 2005.
24. + regulatory T cells: II. Origin, disease models and clinical aspects. APMIS 112: 642-650, 2004.
25. - lymphocytes is thymus and proliferation independent. Cancer Res 66: 4488-4495, 2006.
26. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296, 1998.
27. Ghiringhelli F, Menard C, Martin F and Zitvogel L: The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 214: 229-238, 2006.
28. + regulatory T cells. J Leukoc Biol 81: 144-153, 2006.
29. + regulatory T cells control autoimmunity? Curr Opin Immunol 17: 638-642, 2005.
30. Pakravan N, Hassan AT and Hassan ZM: Naturally Occurring self-reactive CD4(+)CD25(+) regulatory T cells: universal immune code. Cell Mol Immunol 4: 197-201, 2007.
31. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006.
32. + T cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646, 2006.
33. +CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 96: 617-622, 2007.
34. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
35. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H and Fujii H: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3(+) regulatory T cells in gastric cancer. Int J Cancer 122: 2286-2293, 2008.
36. + regulatory T cells cultured with rapamycin. J Immunol 178: 320-329, 2007.
37. + T reg cells. J Exp Med 203: 1701-1711, 2006.
38. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H and Sato M: Possible contribution of active MMP2 to lymphnode metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 70: 120-127, 1997. (Pubitemid 27059715)
39. Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L, D'Amico G, Power CA, Wells TN, Gobbi M, Allavena P and Mantovani A: Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159: 1993-2000, 1997.
40. Fujii-Maeda, S, Kajiwara K, Ikizawa K, Shinazawa M, Yu B, Koga T, Furue M and Yanagihara Y: Reciprocal regulation of thymus and activation-regulated chemokine/macrophage-derived chemokine production by interleukin (IL)-4/IL-13 and interferongamma in HaCaT keratinocytes is mediated by alternations in E-cadherin distribution. J Invest Dermatol 122: 20-28, 2004.
41. Ziegler SF: FOXP3: not just for regulatory T cells anymore. Eur J Immunol 37: 21-23, 2007. (Pubitemid 46128782)
42. + T cells: possible role in atopic dermatitis. J Invest Dermatol 126: 1043-1051, 2006.
43. Bonecchi R, Sozzani S, Stine JT, Luini W, D'Amico G, Allavena P, Chantry D and Mantovani A: Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. Blood 92: 2668-2671, 1998.
44. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT and Whiteside TL: T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14: 3706-3715, 2008.
45. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.
46. + regulatory T cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107: 2866-2872, 2006.
47. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380, 2006.
48. Hori S: Rethinking the molecular definition of regulatory T cells. Eur J Immunol 38: 928-930, 2008.
49. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92: 913-920, 2005.
50. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A and Sinigaglia F: Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 161: 5111-5115, 1998.
51. Shimizu J, Yamazaki S, Takahashi T, Ishida Y and Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142, 2002.
52. Nocentini G, Ronchetti S, Cuzzocrea S and Riccardi C: GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 37: 1165-1169, 2007.
53. Nocentini G and Riccardi C: GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 35: 1016-1022, 2005. (Pubitemid 40542207)
54. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E and Riccardi C: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34: 613-622, 2004.
55. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Del Prete A, Allavena P, Ruco LP, Chiabrando C, Girolomoni G, Mantovani A and Sozzani S: Dendritic cells as a major source of macrophagederived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 31: 812-822, 2001.
56. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A and Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129-134, 1998.
57. Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP and Elias CG 3rd: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 161: 5027-5038, 1998. (Pubitemid 28492085)
58. Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K and Sato S: Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res 298: 38-45, 2006.
59. Mariani M, Lang R, Binda E, Panina-Bordignon P and D'Ambrosio D: Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 34: 231-240, 2004.
60. Jakubzick C, Wen H, Matsukawa A, Keller M, Kunkel SL and Hogaboam CM: Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 165: 1211-1221, 2004.
61. Ishida T and Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 98: 1139-1146, 2006.
62. Yamashita U and Kuroda E: Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 22: 105-114, 2002. (Pubitemid 35244753)
63. Pries R and Wollenberg B: Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17: 141-146, 2006.
64. Pries R, Thiel A, Brocks C and Wollenberg B: Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 20: 45-48, 2006.